Down 13.69%: Is Sage Therapeutics Stock a Bad-News Buy? [The Motley Fool]
Sage Therapeutics, Inc. (SAGE)
Last sage therapeutics, inc. earnings: 2/27 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sagerx.com/investor-relations
Company Research
Source: The Motley Fool
Sage's lead drug candidate whiffs in a late-stage study. George Budwell ( TMFGBudwell ) Sep 12, 2017 at 6:30PM What happened Shares of Sage Therapeutics ( NASDAQ:SAGE ) , a clinical-stage biotech, dropped by 13.69% today, after the company reported that its experimental treatment for super-refractory status epilepticus (SRSE) missed its primary endpoint in a late-stage study. Super-refractory epilepticus is a life-threatening condition defined by severe seizures that continue, or reoccur, 24 hours after anesthetic therapy. Sage's experimental SRSE drug candidate, brexanolone (SAGE-547), was reportedly unable to outperform placebo in terms of reducing the rate of seizures when added to standard of care. Image source: Getty Images. So what As an FDA-approved treatment for SRSE, brexanolone was projected to generate somewhere between $33 mil
Show less
Read more
Impact Snapshot
Event Time:
SAGE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAGE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAGE alerts
High impacting Sage Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SAGE
News
- Ex-Stanford President's AI Drug Startup Pulls In $1 Billion in Commitments [BNN Bloomberg (Canada)]BNN Bloomberg
- Sage Therapeutics, Inc. (NASDAQ: SAGE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal [Yahoo! Finance]Yahoo! Finance
- Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release [Yahoo! Finance]Yahoo! Finance
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Scotiabank from $34.00 to $19.00. They now have a "sector outperform" rating on the stock.MarketBeat
SAGE
Earnings
- 2/14/24 - Beat
SAGE
Sec Filings
- 4/19/24 - Form 8-K
- 4/17/24 - Form 8-K
- 3/27/24 - Form SC
- SAGE's page on the SEC website